MicroRNAs as mediators of drug resistance mechanisms.
Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. Electronic address: [email protected]
Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden Hospital, London and Sutton, UK.
- Published Article
Current opinion in pharmacology
- Publication Date
Sep 05, 2020
MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathways crucial for maintaining cells' homeostasis like apoptosis, differentiation, inflammation and cell-cycle regulation. They act by regulation of gene expression at post-transcriptional level through fine-tuning of target proteins expression. Expression of microRNAs is cell-type specific and since their discovery they have been proven to be deregulated in various disorders including cancer. Several lines of evidence are emerging that link microRNAs to drug resistance mechanisms in tumours given their important role in modulating oncogenic and tumour suppressive mechanisms. This review will focus on latest knowledge of the roles and mechanisms of microRNAs as mediators to drug resistance and the implications for future therapies. Copyright © 2020 Elsevier Ltd. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 10/06/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/32898724